The latest biotech news

News and Trends 17 Jan 2017

This Leading Gas Distributor from France is Going Bio

Global Bioenergies and Butagaz will collaborate to develop and incorporate renewable energy sources into France’s energy systems. Butagaz, a gas distributor from France, is partnering with Global Bioenergies, a synbio company in Paris that produces biofuel with renewable sources. Butagaz will support Global Bioenergies’ industrial development in exchange for the first batches of bio-isobutene the […]

January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

German Antibody for Cancer Diagnostics catches an Australian Eye

Wilex is selling Telix Pharmaceuticals its radiolabeled antibody for cancer applications, Redectane, to focus on the development of ADCs instead. The Australian Telix Pharmaceuticals has closed a license agreement with Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

Merck partners with Big Data Unicorn to help Cancer Patients

Merck will use Palantir’s big data software to improve drug development and patient services, starting with cancer treatments. Merck will step up its data analytics capabilities in partnership with Palantir. The US company, co-founded by PayPal billionaire Peter Thiel, provides data integration and analysis software that Merck plans to use to improve patient care and […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

The UK Steps Up its Game in Automated CRISPR Gene Editing

Horizon Discovery now has full access to CRISPR technology and will develop an automated gene editing platform in collaboration with Solentim. Horizon Discovery, based in Cambridge, UK, uses gene editing technology to create custom cell lines for research. To step up its game, the company has upgraded its existing license with ERS Genomics‘ to obtain […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Jan 2017

RNA Spray fights Viruses and could Sidestep problems with GMOs

RNA and clay could be the future of crop protection and manipulation of plants’ traits. Researchers have managed to use these ingredients to create a spray capable of “vaccinating” plants, teaching them to recognize the genetic material of viruses. RNA-based therapies may have suffered a recent blow in the clinic this week, but when it comes […]

January 13, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 13 Jan 2017

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […]

January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II

Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that tackles the obesity and diabetes epidemic. MorphoSys is a billion euro biotech that develops therapeutic antibodies for big names like Bayer, Pfizer, GSK, Boehringer Ingelheim, Roche and Janssen. The company is now adding type 2 diabetes to its long list of indications; bimagrumab will start Phase […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Jan 2017

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Money doesn’t guarantee success, even if it’s heavy investment from the likes of the Bill & Melinda Gates Foundation. Ingmar Hoerr explains what it means for mRNA therapeutics. In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not […]

January 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 11 Jan 2017

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Jan 2017

Dutch Biotech Takes over Sustainable Coca Cola Bottles Project

Avantium has acquired Liquid Light, getting hold of the last piece of technology it requires to create the next generation of sustainable Coca Cola bottles. Avantium, a spin-off from Shell located in Amsterdam, is one of Coca Cola’s choices to develop its next-generation plastic bottles made 100% from plant-based materials. The biotech is now stepping up […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jan 2017

Stem Cells in your Teeth can be Stimulated to Naturally Repair Cavities

Researchers from the UK have described a new treatment for cavities that could get rid of fillings and cements by employing an Alzheimer’s drug. Most of us have visited the dentist to fill a cavity. The usual procedure involves removing the damaged area and replacing it with mineral materials. But what if you could let […]

January 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

This Leading Gas Distributor from France is Going Bio

German Antibody for Cancer Diagnostics catches an Australian Eye

Merck partners with Big Data Unicorn to help Cancer Patients

The UK Steps Up its Game in Automated CRISPR Gene Editing

RNA Spray fights Viruses and could Sidestep problems with GMOs

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Dutch Biotech Takes over Sustainable Coca Cola Bottles Project

Stem Cells in your Teeth can be Stimulated to Naturally Repair Cavities

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!